Literature DB >> 26236550

Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment.

Sasanka Chakrabarti1, Vineet Kumar Khemka1, Anindita Banerjee2, Gargi Chatterjee1, Anirban Ganguly1, Atanu Biswas3.   

Abstract

Alzheimer's disease (AD), the major cause of dementia among the elderly world-wide, manifests in familial and sporadic forms, and the latter variety accounts for the majority of the patients affected by this disease. The etiopathogenesis of sporadic AD is complex and uncertain. The autopsy studies of AD brain have provided limited understanding of the antemortem pathogenesis of the disease. Experimental AD research with transgenic animal or various cell based models has so far failed to explain the complex and varied spectrum of AD dementia. The review, therefore, emphasizes the importance of AD related risk factors, especially those with metabolic implications, identified from various epidemiological studies, in providing clues to the pathogenesis of this complex disorder. Several metabolic risk factors of AD like hypercholesterolemia, hyperhomocysteinemia and type 2 diabetes have been studied extensively both in epidemiology and experimental research, while much less is known about the role of adipokines, pro-inflammatory cytokines and vitamin D in this context. Moreover, the results from many of these studies have shown a degree of variability which has hindered our understanding of the role of AD related risk factors in the disease progression. The review also encompasses the recent recommendations regarding clinical and neuropathological diagnosis of AD and brings out the inherent uncertainty and ambiguity in this area which may have a distinct impact on the outcome of various population-based studies on AD-related risk factors.

Entities:  

Keywords:  Alzheimer’s disease; Metabolic; pathogenesis; risk factors; sporadic; treatment

Year:  2015        PMID: 26236550      PMCID: PMC4509477          DOI: 10.14336/AD.2014.002

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  184 in total

Review 1.  Novel disease-modifying therapies for Alzheimer's disease.

Authors:  Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study.

Authors:  J Heitner; D Dickson
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

3.  A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons.

Authors:  Erdinç Dursun; Duygu Gezen-Ak; Selma Yilmazer
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  High total cholesterol levels in late life associated with a reduced risk of dementia.

Authors:  M M Mielke; P P Zandi; M Sjögren; D Gustafson; S Ostling; B Steen; I Skoog
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

5.  Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.

Authors:  Elina Zotova; James Ar Nicoll; Raj Kalaria; Clive Holmes; Delphine Boche
Journal:  Alzheimers Res Ther       Date:  2010-01-22       Impact factor: 6.982

6.  Midlife homocysteine and late-life dementia in women. A prospective population study.

Authors:  Dimitri E Zylberstein; Lauren Lissner; Cecilia Björkelund; Kirsten Mehlig; Dag S Thelle; Deborah Gustafson; Svante Ostling; Margda Waern; Xinxin Guo; Ingmar Skoog
Journal:  Neurobiol Aging       Date:  2009-04-01       Impact factor: 4.673

7.  The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Gerontol       Date:  2010-01-11       Impact factor: 4.032

8.  Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.

Authors:  György Paragh; Petra Balla; Evelin Katona; Ildikó Seres; Anikó Egerházi; István Degrell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2002-04       Impact factor: 5.270

Review 9.  Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease.

Authors:  Darryl W Eyles; Thomas H J Burne; John J McGrath
Journal:  Front Neuroendocrinol       Date:  2012-07-11       Impact factor: 8.606

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  41 in total

1.  Allicin ameliorates aluminium- and copper-induced cognitive dysfunction in Wistar rats: relevance to neuro-inflammation, neurotransmitters and Aβ(1-42) analysis.

Authors:  Sunpreet Kaur; Khadga Raj; Y K Gupta; Shamsher Singh
Journal:  J Biol Inorg Chem       Date:  2021-05-22       Impact factor: 3.358

Review 2.  Exercise for the diabetic brain: how physical training may help prevent dementia and Alzheimer's disease in T2DM patients.

Authors:  Sebastian Bertram; Klara Brixius; Christian Brinkmann
Journal:  Endocrine       Date:  2016-05-09       Impact factor: 3.633

3.  Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer's disease.

Authors:  Elizabeth M Ellison; Erin L Abner; Mark A Lovell
Journal:  J Neurochem       Date:  2017-02       Impact factor: 5.372

4.  The short-term improvements of enriched environment in behaviors and pathological changes of APP/PS1 mice via regulating cytokines.

Authors:  Yuwei Zhang; Ge Wang; Lin Wang; Jian Zhao; Rui Huang; Qianying Xiong
Journal:  Hum Vaccin Immunother       Date:  2018-06-01       Impact factor: 3.452

Review 5.  Physiological changes in neurodegeneration - mechanistic insights and clinical utility.

Authors:  Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2018-03-23       Impact factor: 42.937

6.  Disruption of leptin signalling in a mouse model of Alzheimer's disease.

Authors:  Anna King; Anna Brain; Kelsey Hanson; Justin Dittmann; James Vickers; Carmen Fernandez-Martos
Journal:  Metab Brain Dis       Date:  2018-03-15       Impact factor: 3.584

Review 7.  Aptamer and its applications in neurodegenerative diseases.

Authors:  Jing Qu; Shuqing Yu; Yuan Zheng; Yan Zheng; Hui Yang; Jianliang Zhang
Journal:  Cell Mol Life Sci       Date:  2016-08-25       Impact factor: 9.261

8.  The PPARG Pro12Ala Polymorphism and 20-year Cognitive Decline: Race and Sex Heterogeneity.

Authors:  Nancy A West; Jonathan V Tingle; Jeannette Simino; Elizabeth Selvin; Jan Bressler; Thomas H Mosley
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Apr-Jun       Impact factor: 2.703

Review 9.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

Review 10.  Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration.

Authors:  Khalid Bashir Dar; Aashiq Hussain Bhat; Shajrul Amin; Bilal Ahmad Reshi; Mohammad Afzal Zargar; Akbar Masood; Showkat Ahmad Ganie
Journal:  Cell Mol Neurobiol       Date:  2019-10-04       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.